Nesbuvir (previously known as VB-19796 and HCV-796) is an inhibitor of hepatitis C NS5B RNA-dependent RNA polymerase. The drug was tested in phase II in patients with hepatitis C in combination with rebetol and peg-intron, however, its development was terminated due to safety issues.

Clociguanil (BRL 50216, WR 38839) is an antimalarial compound, a derivative of N-benzyloxydihydrotriazine, developed by Beecham Pharmaceuticals. Mode of action studies indicated that clociguanil is a dihydrofolate reductase inhibitor of Plasmodium and is capable of marked potentiation with a selected sulphonamide against both the sensitive N strain and the cycloguanil-resistant B line of P. berghei. A combination of clociguanil and sulphadiazine prevented the development of parasitemia caused by P. falciparum in humans. The subsequent development of clociguanil was discontinued because of a relatively short half-life in man and lack of suppression of pre-erythrocytic schizogony of a strain of P. falciparum resistant to chloroquine, pyrimethamine, and proguanil.

Nitrocycline is a tetracycline antibiotic.

Cyacetacide is a biochemical used in the past as an anti-tuberculosis agent and currently used in Russia to for the treatment of various forms of tubercular lesions of the eye: keratitis, scleritis, uveitis, chorioretinitis, tuberculosis-allergic diseases and eye diseases of non-tubercular origin. Cyacetacide has also been used to derive compounds that may have antitumor properties.

Crotoniazide is a derivative of isonicotinic hydrazide. Crotoniazide demonstrated antituberculous activity in vitro and in vivo.

Clofenoxyde is antifungal and antibacterial agent developed in the 1960s. It is claimed to have activity against gram-positive and gram-negative bacteria.

LAUROGUADINE is a bactericide, topical antiseptic.

Clinafloxacin is a broad-spectrum fluoroquinolone antibiotic that was originally developed and subsequently abandoned in the late 1990s as a human health antibiotic for respiratory diseases. Clinafloxacin displays broad-spectrum antibacterial activity against Gram-positive, Gram-negative, and anaerobic pathogens by inhibiting the bacterial regulatory enzyme DNA gyrase (IC50 = 0.92 ug/ml) as well as topoisomerase IV (IC50 = 1.62 ug/ml).

Opaviraline (also known as GW 420867), a nonnucleoside reverse transcriptase inhibitor that was studied for the treatment of HIV infections. The drug participated in clinical trials phase II in Germany, in South Africa, and in the United Kingdom, however, these studies were discontinued.

Sedecamycin (also known as lankacidin A), a 17-membered macrolide antibiotic that showed potent activity against Treponema hyodysenteriae. This compound was used in veterinary for treating swine dysentery.